Abstract. Colorectal cancer (CRC) is the third most common malignant tumor worldwide, affecting over 1.23 million individuals annually. Over the past several years, the role of microRNAs (miRNAs) in CRC cells have been extensively investigated. Recently, it was discovered that extracellular miRNAs circulate in the blood of healthy individuals as well as CRC patients. Serum circulating miRNAs as novel biomarkers may be a new approach to CRC diagnosis. However, their secretory mechanism and biological function have not been fully elucidated. In this review, the main serum miRNAs used as potential diagnostic biomarkers for CRC, such as miR-92, miR-141, miR-29a, miR-21, miR-221, miR-601 and miR-760, were summarized. In addition, the mechanism of miRNA secretion from CRC cells was discussed. It is recommended that additional studies focus on the usefulness of serum miRNAs for early CRC diagnosis, prognosis and therapeutics.
Introduction
Colorectal cancer (CRC) is the third most common malignant tumor worldwide (1) . Over 1.23 million individuals are diagnosed with CRC and 0.6 million succumb to the disease worldwide annually (2) . Early-stage diagnosis of CRC potentially reduces the mortality of this disease (3) . Although colonoscopic screening for CRC is currently the most reliable diagnostic tool, its cost and invasive nature limit its use. Thus, there is a pressing need for novel, non-invasive, highly sensitive biomarkers to improve the detection of CRC.
microRNAs (miRNAs) are a class of highly conserved short nucleotide non-coding single-stranded RNA molecules (range, 18-22 nucleotides). miRNAs are involved in the regulation of gene expression through post-transcriptional processing as they suppress translation or induce mRNA degradation (4) . Since their discovery in 1993, the altered expression of miRNAs has been associated with cancer. An individual miRNA may affect the expression of various genes and may exert pleiotropic effects on carcinogenesis (5). Overexpression and silencing or switching off of specific miRNAs have been previously described in the carcinogenesis of CRC (6) .
High serum concentrations of highly stable, cell-free miRNAs were also identified (7) (8) (9) . Evidence from a previous study indicated that such miRNAs are secreted into the blood and are involved in regulating the translation of specific protein-coding genes (10) . Serum miRNAs may be measured repeatedly and non-invasively in a wide array of cancer types. Previous studies revealed that circulating tumor-associated miRNAs may serve as diagnostic predictors of various types of cancer (11) (12) (13) . In this review, the potential usefulness of circulating miRNAs in CRC diagnosis was assessed.
Main serum miRNAs in CRC diagnosis
miR-92. Ng et al (14) were the first to perform a quantitative assessment of miRNAs in CRC. They observed the overexpression of miR-17-3p, miR-135b, miR-222, miR-92 and miR-95 in the preoperative serum samples of CRC patients. Their subsequent study on 90 CRC patients and 50 control subjects demonstrated that expression levels of miR-17-3p and miR-92 was elevated in all the CRC patients (P<0.0005). The miR-92 sensitivity was 89% and its specificity was 70%. Huang et al (15) also reported that the sensitivity of miR-92a was 83.0% and its specificity was 84.7% in CRC. This indicated that miR-92 may be a non-invasive molecular marker for CRC diagnosis. (15) conducted a study with plasma samples from 100 patients with CRC, 37 with adenoma and 59 healthy individuals. They identified 12 miRNAs with upregulated expression, including miR-134, miR-146a, miR-17-3p, miR-181d, miR-191, miR-221, miR-222, miR-223, miR-25, miR-29a, miR-320a and miR-92a. The sensitivity of miR-29a was 69% and its specificity was 89.1% for CRC. Tumor-derived plasma miR-29a is a potential CRC diagnostic marker. It was proven that there is an association between miR-29a and CRC TNM stage. In addition, another study detected that serum miR-29a levels were significantly higher in CRC with liver metastasis compared to CRC patients, exhibiting a sensitivity of 75% and a specificity of 75% (AUC of 0.803 at a cut-off of 0.155) in differentiating metastatic from non-metastatic patients (17) . 
Mechanism of miRNA secretion and incorporation
Several studies have explained the mechanisms of action of various miRNAs in CRC. Overexpression or downregulation of specific miRNAs were proven to be correlated with carcinogenesis and metastasis (23, 24) . However, the secretory mechanism and incorporation of extracellular miRNAs in CRC cells has not been elucidated. In certain organisms, such as C. elegans and Drosophila melanogaster, small RNA pathways may spread from cell to cell. In mammalian cells, recent studies demonstrated the importance of communication between cancer cells and their surroundings through exosomes (25, 26) . Kosaka et al (27) suggested that miRNAs are released through a neutral sphingomyelinase 2 (nSM-ase2)-mediated ceramide-dependent secretory machinery. The secretory miRNAs are transferable and functional in the recipient cells. The nSM-ase2, which regulates ceramide biosynthesis, may control the secretion of (22) miRNAs outside the cells. This enzyme is already known for the secretion of exosomes. Another possible mechanism for the secretion of miRNAs involves an apoptotic body, specifically the membranous microvesicles shed from cells during apoptosis (28) . A study conducted by Zernecke et al (28) demonstrated that endothelial cell-derived apoptotic bodies conveyed paracrine alarm signals to recipient cells, which triggered the production of chemokine CXC motif ligand 12 (CXCL12). CXCL12 production was mediated by miR-126. miR-126 was enriched in apoptotic bodies and repressed its target gene in recipient cells. The study also showed that apoptotic bodies may transfer miRNAs between the cells. Of note, it was previously found that phosphatidylserine was detected on the surface of exosomes and apoptotic bodies.
Miyanishi et al (29) identified an antibody that inhibits the phosphatidylserine-dependent engulfment of apoptotic cells and this antibody may also be involved in exosome-mediated intercellular signaling. Although the mechanism of secretion and incorporation of miRNAs has not been elucidated, secretory miRNAs may play a pivotal role as signaling molecules in physiological and pathological events.
Potential value
The mortality and morbidity of CRC have moderately declined and CRC has become a preventable disease, provided the lesions are detected early with screening methods (30) . Therefore, an effective diagnostic method should be applied for the clinical detection of CRC.
The fecal occult blood test (FOBT) is the most widely used screening modality for CRC. It was reported that the sensitivity of a single FOBT for CRC is 30-50% (31) and its specificity for CRC and adenomas is 90-98% (32). Therefore, one of the potential limitations is overdiagnosis. In addition, ingestion of certain foods (red meat, certain fruits and vegetables) and medicines (non-steroidal anti-inflammatory drugs) may yield false-positive results and multiple stool samples may be required.
CEA is the most widely used serum marker in patients with CRC; however, CEA may also be elevated by benign conditions. For example, cirrhosis, inflammatory bowel disease, chronic lung disease and pancreatitis may result in increased blood CEA levels (33) . The specificity of CEA in the identification of occult CRC is high, however, findings of other studies have shown its sensitivity to be extremely low (34) . Accordingly, the use of CEA is not recommended for mass screening (35) .
Certain miRNAs exhibit significantly up-or downregulated levels in the plasma of CRC patients (Table I ). The studies shown in Table I ( [14] [15] [16] 19, 21, 22) indicated that the investigated miRNAs exhibited higher sensitivity and specificity. Serum miRNAs are resistant to digestion by RNase A and are notably stable under other diverse conditions, such as boiling, low/high pH, extended storage and freeze-thaw cycles (36) . Serum miRNAs are not affected by the location or blood loss of the neoplasms. Furthermore, they show promise as potential biomarkers with a high stability. Several current studies suggest that deregulation of miRNAs is closely linked to cancer incidence (37) . Therefore, it is anticipated that circulating serum miRNAs may become novel methods for reducing the false-positive and false-negative results of the conventional diagnostic methods (10).
Limitations
Biomarkers capable of detecting TNM stage I or II cancers may bear the highest potential for reducing the mortality and overall health burden caused by CRC. However, the association between serum miRNAs and the early stage of CRC was seldom revealed by previous studies. In addition, the application of serum miRNAs is associated with a high cost and a long latency time, which may limit screening for a wide range of patients (38) .
The availability of data regarding the association of age and health status with the dynamic changes of the serum from different CRC patients is currently limited. As a result, it may be necessary to include a wide number of CRC patients exhibiting factors such as comorbidities and lifestyle variations, which may modify the miRNA levels (39).
Conclusions
The identification of serum miRNAs has significantly altered the view on gene regulation and the different serum miRNA expressions have attested the presence of CRC. Additional studies should focus on early-stage CRC detection and evaluation of disease progression following surgery (40) . Premalignant lesion (e.g., adenoma) detection by serum miRNAs is more valuable for CRC prevention. Furthermore, investigation of the mechanisms underlying miRNA secretion and the dynamic progress of miRNAs in the circulation is necessary. It is recommended that prospective studies are replicated in a number of large independent populations to evaluate the feasibility of their results. A combination of biomarkers may improve the diagnostic accuracy. Therefore, it may be useful to evaluate the combination of the microRNA diagnostic biomarker with other available screening tests. A moderate number of miRNAs may be sufficient to differentiate cancerous from normal tissue, taking into consideration practice value and cost.
